Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH-22
- Development stage
- Unknown
- Lead developer
- Curanter
- Administration
- Oral
01
Overview
CH-22 is a homeopathic remedy developed and marketed by Curanter Homeo (also referred to as Cusrnter Homeo), a homeopathic product retailer based in Patna, India. The product is part of a commercial series (CH-19 through CH-31) and is available in oral formulations, including both drops and tablets. As a homeopathic preparation, CH-22 does not have a documented pharmacological mechanism of action, specific biological targets, or clinical trial data associated with its development. It is positioned as a finished retail product for consumer use rather than a therapeutic candidate in a traditional pharmaceutical R&D pipeline.
- Brand names
- CH-22CH22CH 22
- Other names
- CH-22 dropsCH22 dropsCH 22 dropsCH-22 tabletsCH22 tabletsCH 22 tablets
Beyond the preview
Go deeper on CH-22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH-22.